Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about BCRX, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Peramivir FDA approved Dec 2014 · Rapivab |
Influenza | Phase 3 · NCT01224795 | Withdrawn |
| Berotralstat FDA approved Dec 2020 · Orladeyo |
Hereditary Angioedema | Phase 3 · NCT05453968 | Active not recruiting |
| Oseltamivir | Influenza | Phase 3 · NCT02369159 | Completed |
| Avoralstat | Hereditary Angioedema | Phase 3 · NCT02670720 | Terminated |
| BCX4161 | Hereditary Angioedema | Phase 2/3 · NCT02303626 | Completed |
| BCX7353 | Hereditary Angioedema | Phase 2/3 · NCT03472040 | Completed |
| Forodesine Hydrochloride | Leukemia, Lymphocytic, Chronic | Phase 2 · NCT00289549 | Completed |
| Ulodesine | Gout | Phase 2 · NCT01265264 | Completed |
| Forodesine | Cutaneous T-cell Lymphoma (CTCL), | Phase 2 · NCT00501735 | Completed |
| Pelecopan (BCX9930) | Paroxysmal Nocturnal Hemoglobinuria (PNH) | Phase 2 · NCT05116787 | Terminated |
| Galidesivir (BCX4430) | Marburg Virus Disease | Phase 1 · NCT03800173 | Completed |
| BCX7353 and probes | Hereditary Angioedema | Phase 1 · NCT02819102 | Completed |
| Rosuvastatin | Hereditary Angioedema | Phase 1 · NCT03136237 | Completed |
| BCX17725 | Netherton Syndrome | Phase 1 · NCT06539507 | Active not recruiting |
| BCX10013 | Paroxysmal Nocturnal Hemoglobinuria | Phase 1 · NCT06100900 | Completed |
Also used in these trials (approved or third-party drugs, not BCRX's own candidates): Ravulizumab, Eculizumab, Digoxin, Cyclosporine.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
BCRX holds $375M in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.
Dilution pressure: 7 · Low
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when BCRX files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Deerfield Mgmt, L.P. | 5%+ holder (13G) | 14,341,000 | 5.57% | 2025-12-31 |
| Vanguard Capital Management | Institution (13G, 5%+) | 12,961,172 | 5.04% | 2026-03-31 |
| Jon P Stonehouse Director · +33,540 options |
Insider | 1,420,419 | 0.55% | 2026-08-31 |
| Charles K Gayer President and CCO · +1.00M options |
Insider | 952,583 | 0.37% | 2025-12-19 |
| Alane P Barnes Chief Legal Officer · +255,050 options |
Insider | 400,703 | 0.16% | 2026-05-13 |
| Babar Ghias Chief Financial Officer · +355,050 options |
Insider | 268,700 | 0.10% | 2025-12-17 |
| Ronald Dullinger Chief Commercial Officer |
Insider | 258,372 | 0.10% | 2026-01-01 |
| Sandeep Menon Chief R&D Officer · +441,350 options |
Insider | 205,150 | 0.08% | 2026-04-06 |
| Vincent Milano Director · +33,540 options |
Insider | 109,642 | 0.04% | 2026-08-31 |
| Steven K Galson Director · +33,540 options |
Insider | 86,165 | 0.03% | 2026-06-11 |
| Theresa Heggie Director · +33,540 options |
Insider | 80,646 | 0.03% | 2026-06-11 |
| Alan G Levin Director · +33,540 options |
Insider | 79,565 | 0.03% | 2026-06-11 |
Share count 257,299,269 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
| Date | Drug | Type | Run-up 30d | Decision 1d | After 5d |
|---|---|---|---|---|---|
| 2025-09-12 | — | NDA | -3.4% | -2% | -1.4% |
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for BCRX and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →